Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FELQP
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for pharmaceutical products and medical consumables. This firm fixed-price delivery order, awarded December 2, 2025, represents one of numerous orders issued to DMS Pharmaceutical Group under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The delivery order carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement and was selected based on competitive capability. DMS Pharmaceutical Group maintains a single-award Indefinite Delivery Contract under PPV-G GEN V designated SPE2DR, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to military medical facilities worldwide, encompassing branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialized medical consumables. DMS Pharmaceutical Group's product portfolio includes oncology treatments, immunosuppressants, emergency medications, surgical products, and routine pharmaceuticals, demonstrating its capacity to fulfill diverse pharmaceutical requirements across the federal military medical system. The contract structure authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs with no identified subcontractor relationships, enabling DMS Pharmaceutical Group to serve as a dedicated supplier to support ongoing Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DU26FELQP?
SPE2DU26FELQP was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DU26FELQP worth?
The government has obligated $10,485 on SPE2DU26FELQP.
Is contract SPE2DU26FELQP an order under another contract?
Yes. SPE2DU26FELQP is a delivery order under SPE2DU25D9421, an indefinite delivery contract.
Was contract SPE2DU26FELQP competed?
The extent of competition for SPE2DU26FELQP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award